Objective-To identify proteins related to intraluminal thrombus biological activities that could help to find novel pathological mechanisms and therapeutic targets for human abdominal aortic aneurysm (AAA). Approach and Results-Tissue-conditioned media from patients with AAA were analyzed by a mass spectrometry-based strategy using liquid chromatography coupled to tandem mass spectrometry. Global pathway analysis by Ingenuity software highlighted the presence of several circulating proteins, among them were proteins from the complement system. Complement C3 concentration and activation were assessed in plasma from AAA patients (small AAA, AAA diameter=3-5 cm and large AAA, AAA diameter >5 cm), showing decreased C3 levels and activation in large AAA patients. No association of a combination of single-nucleotide polymorphisms in complement genes between large and small AAA patients was observed. Intense extracellular C3 inmunostaining, along with C9, was observed in AAA thrombus. Analysis of C3 in AAA tissue homogenates and tissue-conditioned media showed increased levels of C3 in AAA thrombus, as well as proteolytic fragments (C3a/C3c/C3dg), suggesting its local deposition and activation. Finally, the functional role of local complement activation in polymorphonuclear (PMN) cell activation was tested, showing that C3 blockade by anti-C3 antibody was able to decrease thrombus-induced neutrophil chemotaxis and reactive oxygen species production.
C linical and pathophysiological evidence indicates that intraluminal thrombus (ILT) plays a role in the evolution of abdominal aortic aneurysms (AAA). 1 The eccentric distribution of the ILT was associated with continuous expansion, 2 and aortic ILT volume is associated with AAA growth. [3] [4] [5] It has been reported that large ILT areas were significantly associated with increased AAA expansion. 3 Speelman et al 4 demonstrated that larger ILT in AAA was not only associated with a higher AAA growth rate, but also with a lower wall stress. These data suggest that weakening of the AAA wall, under the biological dynamics of ILT, might play a more imminent role in the process of AAA growth than the stress acting on the wall. A recent study has confirmed the association of ILT volume with AAA growth and also with cardiovascular events. 5 Finally, radiological signs of ILT lysis could precede aortic rupture (crescent sign). 1 In parallel, accumulating data suggest that biological activities associated with leukocyte, platelet, and red blood cell accumulation in ILT play an important role in AAA progression. [6] [7] [8] [9] [10] [11] Thus, the identification of novel proteins related to ILT biological activities could help to find novel pathogenic mechanisms, as well as therapeutic targets, of AAA. In previous studies, following a strategy based on the analysis of AAA tissueconditioned media by gel-or array-based proteomic techniques, we identified proteins related to different pathological processes involved in AAA, such as oxidation 10 and proteolysis. 12 To further explore the pathophysiology of ILT in human AAA by increasing the number of identified proteins, ILT and wallconditioned media were analyzed in this study using liquid chromatography and tandem mass spectrometry (MS). Global pathway analysis of identified peptides/proteins by Ingenuity software highlighted that complement system components were highly enriched in AAA tissue-conditioned media.
The complement system plays a major role in innate immunity, participating in host defense responses against microorganisms via opsonization, chemoattraction of leukocytes, cell activation, and bridging innate and adaptive immunity. [13] [14] [15] [16] However, disturbances in this defense machinery contribute to the pathogenesis of various autoimmune diseases, such as systemic lupus erythematosus. Systemic lupus erythematosus is characterized by decreased circulating complement components associated with their deposition and activation in host tissues. As complement proteins are mainly synthesized by the liver, we hypothesized that the high levels of complement peptides/proteins identified in AAA thrombus-conditioned media could be related to its trapping from the blood and by increased proteolytic activation. To test this hypothesis, we first assessed C3 concentration and activity in blood of AAA patients at different stages of the disease. Second, we analyzed the presence and activation of C3 in AAA tissue and tissue-conditioned media. Finally, we studied the effect of complement activation in human AAA thrombus on neutrophil chemotaxis and oxidation, key mechanisms involved in AAA pathogenesis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Liquid Chromatography and Tandem MS Analysis of Proteins From AAA Tissue-Conditioned Media
Proteins obtained from AAA thrombus-and wall-conditioned media were trypsin digested, and the resulting peptides were then fractionated by 2-dimensional liquid chromatography using a strong cation exchange column followed by C18 reversed phase chromatography. Finally, the MS and MS/MS spectra were used for protein identification. Table II in the online-only Data Supplement lists all the proteins identified in AAA tissue supernatants, where 60% of them were classically secreted. To organize identified proteins, Ingenuity software was used to find the most enriched canonical pathways in our samples. A total of 257 proteins extracted from the protein lists corresponding to thrombus and wall layer supernatants were analyzed in the same data set. Among others, coagulation and complement systems have been found as relatively enriched in the AAA tissue supernatants (compared with the human genome database; Figure 1A ). Interestingly, several complement-related proteins (eg, C3, C9, clusterin, factor H) were identified, which are represented in gray color in Figure 1B .
Systemic C3 Concentrations and Activity in AAA Patients
As C3 is the central molecule in the complement cascade, we analyzed serum concentrations of C3 in a first cohort of healthy controls (n=28) and AAA patients at follow-up (small AAA, AAA diameter=3-5 cm [n=62]) or at surgery (large AAA, AAA diameter >5 cm, [n=28]). Clinical characteristics are shown in Tables 1 and 2. Increased C3 concentrations were observed in small AAA patients compared with both controls and large AAA patients (controls=148±5 versus small AAA=177±4 versus large AAA=124±8 mg/dL; P<0.01). Logistic regression analysis showed that association between increased C3 in small AAA patients and controls remained significant when adjusted by age but was lost when adjusted for risk factors (not shown), whereas the decreased C3 in large versus small AAA patients persisted after adjustment for risk factors (Table III in the online-only Data Supplement). Plasma C3 concentrations correlated with lipid levels (r=0.4 for lowdensity lipoprotein and triglycerides and r=−0.4 for highdensity lipoprotein; P<0.001 for all) and aortic size (r=−0.4; P<0.005). Linear regression analysis between C3 and aortic size was also independent of risk factors (Table IV in the online-only Data Supplement).
To confirm previous data, we further analyzed a second cohort of patients (Tables 1 and 2), showing that large AAA patients (n=39) have significantly decreased C3 plasma concentrations compared with small AAA patients (n=26; 122±4 versus 138±4 mg/dL; P<0.01; Figure 2A ), which persisted after adjustment for risk factors ( Table III in the online-only Data Supplement). A nonsignificant negative correlation was shown for C3 and aortic size (r=−0.2; P=0.1; Figure 2C ). To test whether complement activity is modified in plasma of AAA patients at different stages of evolution, we performed an alternative pathway (AP) 50 assay that measures the ability of the patient's plasma to lyse rabbit erythrocytes. Accordingly, large AAA patients have decreased complement activity compared with small AAA patients (42±5 versus 75±4% lysis; P<0.01; Figure 2B ). Logistic regression analysis showed that the significant association between AP50 in large AAA compared with small AAA patients persisted after adjustment for risk factors (Table III in the online-only Data Supplement). AP50 correlated with aortic size (r=−0.4; P<0.005; Figure 2D ), which persisted after adjustment for risk factors (Table IV in 
Genetic Association Study
No association of single-nucleotide polymorphisms (SNPs) in the complement cascade in AAA patient and control studies has been recently described. 17, 18 To get further insight into a potential genetic association between complement and AAA evolution, we analyzed whether the decrease in C3 concentrations and activity in large versus small AAA patients could be related to a particular combination of SNPs in complement genes (complotypes), as described for other disorders, such as age-related macular degeneration. 19 However, no association was found between these complotypes and AAA in patients at different stages of the disease (large versus small AAA). In plasma samples available from these patients (n=138), we further confirmed that C3 concentrations were decreased in large AAA patients (n=66) compared with small AAA patients (n=72; 194±5 versus 210±5 mg/dL; P<0.05). Logistic regression analysis showed that the significant association between decreased plasma C3 in large AAA compared with small AAA patients persisted after adjustment for risk factors (Table III in 
Local Complement Retention and Activation in AAA
We analyzed the presence of C3 in AAA tissue by immunohistochemistry, showing an intense extracellular staining in the ILT and, to a lesser extent, in the wall, whereas healthy wall shows weak staining ( Figure 3A) . Similarly, high C9 staining was observed in AAA thrombus compared with wall and healthy wall ( Figure I in the online-only Data Supplement). Interestingly, C3 and C9 deposition was observed in similar areas of the thrombus, suggesting complement activation ( Figure 3B ). Whereas C3 was mainly present in acellular areas of the thrombus, C3 in the wall was also associated with α-actin-positive cells in the media ( Figure II Western blot of tissue homogenates. No detectable C3 mRNA was obtained from 3 of 6 thrombi analyzed, and very low levels were observed in the rest (0.01±0.02 a.u.). No differences were observed in C3 mRNA levels between healthy and AAA wall (0.22±0.1 versus 0.28±0.05 a.u., not shown). In contrast, C3 protein levels in tissue homogenates were higher in ILT compared with pathological wall and healthy wall, confirming the results observed by immunohistochemistry ( Figure 4A ). We further tested C3 concentration and activation in the conditioned media of human ILT and wall of AAA, as well as in healthy media. C3 levels were increased in the AAA thrombus compared with the pathological wall and healthy wall (5.6±0.5 versus 2.4±0.2 versus 0.9±0.2 µg/mL; P<0.001 for all comparisons). Furthermore, C3 proteolytic fragments of 35 to 40 kDa (corresponding to the molecular weight of C3c/C3dg; Figure 4A -4C) appear mainly in tissue and tissue-conditioned media of ILT and, to a lesser extent, in the wall (media and adventitia) of AAA, whereas almost no proteolytic fragments were observed in healthy wall. Because complement activation could involve proteolytic degradation of C3 by proteases, such as plasmin or elastase, 13 abundantly present in ILT, 6, 7 we assessed whether proteolysis of C3 in the thrombus of AAA could take place ex vivo. In this respect, when native C3 was incubated with the luminal part of the thrombus, the 35 to 40 kDa fragments observed in ILT-conditioned media were increased ( Figure 4D ).
Role of Complement Activation in AAA Thrombus-Induced PMN Chemotaxis and Activation
As we did not observe the first fragment of C3 activation, C3a, by Western blot probably as a result of its low molecular weight, we analyzed the presence of C3a in tissue-conditioned media by ELISA. We have observed that C3a levels are increased in ILT compared with the wall of AAA and also the healthy wall (P<0.001 for all comparisons; Figure 5A ). Furthermore, because C3a is involved in PMN chemotaxis and reactive oxygen species production, we address the functional role of complement activation by proteolysis in ILT. Neutrophils were allowed to migrate through a filter into a lower chamber containing thrombus-conditioned media, and the effect of C3 blocking was assessed. Neutrophils were attracted by luminal thrombus, and C3 blockade by anti-C3 antibody was able to decrease such effect (P<0.001; Figure 5B ). Similar effect was observed when native C3 was used as a positive control (not shown). Furthermore, incubation of thrombus-conditioned media with fresh neutrophils increased reactive oxygen species levels, which was prevented by anti-C3 antibody ( Figure 5C ).
Discussion
In the present article, the combination of nano-liquid chromatography and LTQ-Orbitrap MS allowed us to identify larger lists of proteins from AAA tissue-conditioned media compared with array or gel-based approaches. 10, 12 Several proteins previously associated with different AAA pathological mechanisms have been identified (eg, immune-inflammatory response [clusterin], thrombosis [fibrinogen]). Interestingly, a recent proteomic study has also shown increased levels of clusterin, a complement lysis inhibitor able to block the terminal complement cascade in AAA thrombus-conditioned media. 20 In contrast, clusterin concentrations were decreased in AAA plasma, and the authors suggested that ILT could sequester systemic proteins. 20 In agreement, the functional distribution of the identified proteins in our study has shown an enrichment in circulating proteins (eg, coagulation and complement systems). As complement proteins are mainly synthesized by the liver, we hypothesized that the high levels of complement peptides/proteins identified in AAA thrombus-conditioned media could be related to its trapping from the blood and by increased proteolytic activation. We first analyzed C3 concentrations in AAA patients and controls. Circulating C3 levels were increased in small AAA patients compared with controls, probably suggesting an initial hepatic response to vascular injury. However, when we performed a multivariate analysis, including risk factors, no significant differences were observed between small AAA patients and controls in agreement with previous data, 21 discarding its potential use as a diagnostic biomarker. Regarding risk factors, we have observed a positive correlation between C3 and lipid levels. Lipids have been previously suggested as a potential mechanism leading to complement activation in experimental and human hypercholesterolemia. 22 Furthermore, it has been proposed that IgG is an initial mechanism leading to C3 activation in an experimental model of AAA, 23 and increased IgG concentrations have been recently observed in small AAA patients versus controls. However, IgG concentrations decline in large AAA patients. 24 In agreement, we have shown that C3 concentrations are decreased in large compared with small AAA patients, which was independent of different risk factors. In addition, when we performed an AP50 assay to test whether complement activity is modified during AAA evolution, we showed a negative association of complement activity with later stages of disease and with aortic size, independent of risk factors. On the whole, our data suggest that systemic C3 increases in the initial phases of AAA, probably as a response to injury of the wall to increased lipid and IgG concentrations, whereas a decrease in systemic complement concentration and activation takes place in the later stages of AAA.
Complement deficiencies (inherited or acquired) could be linked to the development of autoimmunity, as shown in systemic lupus erythematosus where decreased complement components are observed. To check whether genetic anomalies in complement genes could take place in AAA evolution, we performed a genetic study analyzing a particular combination of SNPs in complement genes (complotypes). This approach has been also described for other disorders, such as age-related macular degeneration. 19 No association on any of the combination of SNPs analyzed was found between small and large AAA patients, similar to previous studies where those individual SNPs were assessed in AAA patients and controls. 17, 18 It has been suggested that the acquired diminution in circulating complement proteins in autoimmune diseases could be associated with deposition of complement components in host tissue. 13 In this respect, complement proteins have been previously detected in human AAA wall. 17, 25, 26 We observed that C3 protein levels were increased in tissue and tissue-conditioned media of AAA wall compared with healthy aortic wall, whereas C3 mRNA is similarly present in pathological and healthy wall in agreement with Hinterseher et al. 17 But, Hinterseher et al 17 did not show C3 staining in the thrombus. In contrast, we have shown that human AAA thrombus displays an intense extracellular staining, along with increased protein levels in tissue homogenates and tissueconditioned media of ILT compared with wall. Differences between both immunohistological studies could be related to the different antibodies used. Furthermore, C3 in thrombus from acute myocardial infarction has also been observed. 27 Because the liver is the major source of complement proteins in humans and low/undetectable C3 mRNA levels were observed in thrombus homogenates, the high extracellular levels of C3 observed in AAA thrombus should be associated with its retention from serum and subsequent activation. In this regard, high C9 immunostaining was also shown in acellular areas of the thrombus and wall compared with healthy wall. In agreement, Pagano et al 26 showed C5B9 in the luminal side of the wall, whereas no staining was observed in healthy wall. Similarly, Tulamo et al 28 also observed complement activation and C5B9 formation in the less cellular part of intracranial artery aneurysm wall. Finally, we showed intense C9 immunostaining associated with C3 deposition, suggesting complement activation in AAA thrombus.
Complement activation involves the classical pathway, the lectin pathway, the AP, and the extrinsic pathway. 13 The classical pathway can be activated by antibodies or by other stimulus, such as C-reactive protein. The AP is part of the innate (nonantigen-specific) immune system and is important in antibodyindependent defense against bacterial infection. The extrinsic pathway involves proteolytic degradation of C3 by proteases, such as elastase, and phagocytes. Furthermore, other components of the coagulation system, such as plasmin, could also participate in complement activation. 16 In this respect, human AAA thrombus could be a privileged site for complement activation because proteases and PMNs are abundant in the ILT of AAA. 6, 7 When we analyzed C3 levels in AAA tissue and tissueconditioned media by Western blot, we observed proteolytic fragments of C3 in AAA thrombus and thrombus-conditioned media. Furthermore, these products of C3 proteolysis and activation were increased when native C3 protein was coincubated with the luminal part of AAA, supporting that in vivo proteolysis of C3 protein could take place within the thrombus of AAA. In addition, C3c/C3dg levels were increased in AAA wall compared with healthy wall. These proteolytic products could participate in the shift from innate to adaptive immunity, characteristic of the adventitial response in AAA. 29 Finally, given that C3a is released in the initial step of the proteolytic processing of C3, C3a levels were assessed in AAA tissue and healthy wall. In agreement with the results obtained for C3, C3a was increased in conditioned media of ILT and wall compared with healthy aorta wall, further supporting proteolysis of C3 in AAA tissue. C3aR mRNA is upregulated in AAA tissue, 17 favoring the potential interaction with C3a in AAA and its functional consequences. In this respect, it is already described that the complement acts as a critical mediator of neutrophil recruitment in AAA mice lesions. 26 Interestingly, we have observed that PMN chemotaxis induced by the ILT could be modulated by incubation with an anti-C3 antibody. Furthermore, C3a has been involved in PMN respiratory burst. 30 We observed that nicotinamide adenine dinucleotide phosphate-oxidasedependent reactive oxygen species production is increased when fresh PMNs are incubated with ILT-conditioned media, and this effect was prevented by C3 blockade. In any case, we should take into account that these functional activities of the thrombus could be also related to the presence of other factors, such as tissue factor, clotting factors (eg, Xa), or thrombin, among others. Thrombin is involved in the activation of the complement system, further confirming a coordinated action of the coagulation and complement systems. 16 immunothrombus. Thrombin also modulates fibrinolysis by activating the plasma carboxypeptidase, thrombin-activatable procarboxypeptidase B. In this respect, enhanced AAA formation in procarboxypeptidase B −/− mice was observed to be associated with plasmin generation. 32 On the whole, all these data suggest that complement activation by proteases present in the thrombus could contribute to AAA pathogenesis. Several studies have recently demonstrated that genetic modification of different mediators of the complement pathway could reduce experimental AAA formation. 23, 26 However, complement activation is modulated by several complement inhibitors (eg, CD59, vitronectin). In this respect, Tulamo et al 28 showed a differential distribution of complement inhibitors in different areas of the wall of intracranial artery aneurysms. These data suggest that a disturbed complement regulation is associated with an increased susceptibility to complement activation and inflammation and may be also cell loss. 28 In our previous study, vitronectin was shown to be downregulated in tissue of ruptured AAA compared with nonruptured AAA. 33 Finally, deficiency of CD59 accelerated, whereas transgenic overexpression of human CD59 attenuated, the progression of experimental AAA. 34 At the therapeutic level, anti-C5 blockade was able to reverse atherosclerosis associated with a decrease in complement deposition. 35 Because atherosclerosis and AAA share some pathological mechanisms, it could be interesting to address whether the therapeutic modulation of complement activators or inhibitors may have a protective role in AAA progression.
On the whole, the decrease of systemic C3 concentration and activity in the later stages of AAA associated with local complement retention, consumption, and proteolysis in the thrombus could induce PMN activation, playing a detrimental role in AAA. Future studies targeting complement activation could be an attractive therapeutic strategy to prevent AAA progression. , thrombus preincubated with anti-C3 (T+anti-C3 at 1:100 or 1:10 dilution), and thrombus preincubated with anti-IgG (T+IgG, for nonspecific chemotaxis). *P<0.001 for anti-C3 vs T. C, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH)-dependent reactive oxygen species (ROS) production in PMNs stimulated during 2 minutes with thrombus-conditioned media, thrombus preincubated with anti-C3 (T+anti-C3 at 1:100 or 1:10 dilution), or thrombus preincubated with anti-IgG (T+IgG). *P<0.05 for anti-C3 vs T.
